Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Amortization - Goodwill Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Mesa Laboratories (MLAB) Long-Term Debt Repayments (2016 - 2025)

Mesa Laboratories' Long-Term Debt Repayments history spans 15 years, with the latest figure at $8.7 million for Q4 2025.

On a quarterly basis, Long-Term Debt Repayments fell 7.96% to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.3 million, a 39.32% increase, with the full-year FY2025 number at $71.6 million, up 113.61% from a year prior.
Long-Term Debt Repayments hit $8.7 million in Q4 2025 for Mesa Laboratories, up from $5.9 million in the prior quarter.
Over the last five years, Long-Term Debt Repayments for MLAB hit a ceiling of $71.6 million in Q2 2024 and a floor of -$54.7 million in Q3 2024.
Historically, Long-Term Debt Repayments has averaged $8.5 million across 5 years, with a median of $8.3 million in 2022.
The widest YoY moves for Long-Term Debt Repayments: up 794.5% in 2024, down 583.56% in 2024.
Tracing MLAB's Long-Term Debt Repayments over 5 years: stood at $10.0 million in 2021, then decreased by 20.0% to $8.0 million in 2022, then surged by 175.0% to $22.0 million in 2023, then tumbled by 57.1% to $9.4 million in 2024, then decreased by 7.96% to $8.7 million in 2025.
Business Quant data shows Long-Term Debt Repayments for MLAB at $8.7 million in Q4 2025, $5.9 million in Q3 2025, and $7.4 million in Q2 2025.